The FDA has given Abbott approval for its RealTime CMV molecular test, a PCR-based assay designed to facilitate the management of hematopoietic stem cell transplant patients receiving cytomegalovirus treatment. The test, which is intended to be run on the company's m2000 RealTime platform, has the ability to amplify two select regions of the cytomegalovirus genome, reducing the risk of detection failure or underquantitation.
Abbott's molecular CMV test wins FDA approval
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.